Cardiovascular disease (CVD) is the leading cause of death globally, accounting for more than 30% of all deaths worldwide. Robust research and evidence-based therapeutic strategies are necessary to reduce the global burden of CVD and its downstream effects on other organ systems. Numerous studies have demonstrated that the various etiologies of CVD are complex and multiple genetic and environmental components likely contribute to the observed clinical manifestations. Elucidation of the genetic and epigenetic networks that contribute to CVD pathogenesis, progression, and response to therapy are necessary to identify risk factors, preventative strategies, and appropriate therapeutic targets. Additionally, with recent advances in gene editing technologies, there is growing interest in employing various gene therapies to tackle adverse cardiac and metabolic phenotypes associated with CVD. Moreover, there is significant patient variability in response to cardiovascular and metabolic disease therapies, which contribute to treatment failure and adverse outcomes in some patients. Therefore, the promise of pharmacogenetics offers the potential to optimize CVD treatment strategies and improve outcomes in the CVD population.
This research topic focuses on the recent advances and challenges related to the intersection of genetics, gene regulation, and metabolic dysfunction in CVD, and the potential for pharmacogenetics and DNA and RNA-based therapeutic interventions.
We encourage submissions of Original Research, Review Articles, Mini-reviews, Opinion Pieces, Methods, and Perspective Articles that encompass a wide range of topics, including, but not limited to the following:
• Genetic and epigenetic networks that contribute to CVD pathogenesis, progression, and response to therapy
• Crosstalk between cardiac metabolism and genetic, epigenetic, and post-transcriptional gene regulation
• Genetic, epigenetic, and post-transcriptional modulation of other-organ anomalies related to CVD
• Inherited disorders of cardiac metabolism
• The pharmacogenetics of CVD therapies
• The use of gene therapy-related strategies for the treatment of CVD and cardiometabolic disease.
Cardiovascular disease (CVD) is the leading cause of death globally, accounting for more than 30% of all deaths worldwide. Robust research and evidence-based therapeutic strategies are necessary to reduce the global burden of CVD and its downstream effects on other organ systems. Numerous studies have demonstrated that the various etiologies of CVD are complex and multiple genetic and environmental components likely contribute to the observed clinical manifestations. Elucidation of the genetic and epigenetic networks that contribute to CVD pathogenesis, progression, and response to therapy are necessary to identify risk factors, preventative strategies, and appropriate therapeutic targets. Additionally, with recent advances in gene editing technologies, there is growing interest in employing various gene therapies to tackle adverse cardiac and metabolic phenotypes associated with CVD. Moreover, there is significant patient variability in response to cardiovascular and metabolic disease therapies, which contribute to treatment failure and adverse outcomes in some patients. Therefore, the promise of pharmacogenetics offers the potential to optimize CVD treatment strategies and improve outcomes in the CVD population.
This research topic focuses on the recent advances and challenges related to the intersection of genetics, gene regulation, and metabolic dysfunction in CVD, and the potential for pharmacogenetics and DNA and RNA-based therapeutic interventions.
We encourage submissions of Original Research, Review Articles, Mini-reviews, Opinion Pieces, Methods, and Perspective Articles that encompass a wide range of topics, including, but not limited to the following:
• Genetic and epigenetic networks that contribute to CVD pathogenesis, progression, and response to therapy
• Crosstalk between cardiac metabolism and genetic, epigenetic, and post-transcriptional gene regulation
• Genetic, epigenetic, and post-transcriptional modulation of other-organ anomalies related to CVD
• Inherited disorders of cardiac metabolism
• The pharmacogenetics of CVD therapies
• The use of gene therapy-related strategies for the treatment of CVD and cardiometabolic disease.
